
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934
(Amendment No. 11)*

Oragenics, Inc.
(Name of Issuer)

Common Stock, par value \$0.001 per share
(Title of Class of Securities)

684023 30 2
(CUSIP Number)

Mark A. Catchur
Shumaker, Loop & Kendrick LLP
101 E. Kennedy Blvd. Suite 2800
Tampa, FL 33602
(813) 229-7600

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 17, 2018
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)	
	Koski Family Limited Partnership 75-2707549	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3.	SEC Use Only	
4.	Source of Funds (See Instructions) PF	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6.	Citizenship or Place of Organization Texas	
Number of shares beneficially owned by each reporting person with	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,828,419 (1) (See Item 5)
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,828,419 (1) (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 1,828,419 (See Item 5)	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
13.	Percent of Class Represented by Amount in Row (11) 15.1%(2)	
14.	Type of Reporting Person (See Instructions) PN	

- (1) Includes (i) 1,286,483 shares of Oragenics Inc. common stock held directly; (ii) 300,000 shares of common stock able to be acquired upon conversion of Series B Preferred Stock and (iii) 241,936 shares of common stock able to be acquired based on warrants exercised.
- (2) Based upon 12,075,571 shares of Company common stock consisting of (i) 11,533,635 shares outstanding as of August 1, 2018; (ii) 300,000 shares of common stock able to be acquired upon conversion of Series B Preferred Stock; and (iii) 241,936 shares of common stock able to be acquired based on warrants able to be exercised.

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Christine L. Koski
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3.	SEC Use Only
4.	Source of Funds (See Instructions) Not applicable
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6.	Citizenship or Place of Organization United States
Number of shares beneficially owned by each reporting person with	7. Sole Voting Power 157,254 (3) (See Item 5)
	8. Shared Voting Power 1,828,419 (1) (4) (See Item 5)
	9. Sole Dispositive Power 157,254 (See Item 5)
	10. Shared Dispositive Power 1,828,419 (1) (4) (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 1,985,673 (See Item 5)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="checkbox"/>
13.	Percent of Class Represented by Amount in Row (11) 16.4% (2)
14.	Type of Reporting Person (See Instructions) IN

(3) Includes 157,254 shares of Oragenics Inc. common stock held directly by the reporting person.

(4) Represents shares beneficially owned by the Koski Family Limited Partnership (“KFLP”) of which Ms. Koski is a general partner and may be deemed to have beneficial ownership. Ms. Koski disclaims beneficial ownership of the shares held by the KFLP except to the extent of her pecuniary interest.

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Robert C. Koski
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3.	SEC Use Only
4.	Source of Funds (See Instructions) Not applicable
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6.	Citizenship or Place of Organization United States
Number of shares beneficially owned by each reporting person with	7. Sole Voting Power 189,208 (5) (See Item 5)
	8. Shared Voting Power 1,828,419 (1) (6) (See Item 5)
	9. Sole Dispositive Power 189,208 (5) (See Item 5)
	10. Shared Dispositive Power 1,828,419 (1) (6) (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 2,017,627 (See Item 5)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="checkbox"/>
13.	Percent of Class Represented by Amount in Row (11) 16.7% (2)(6)
14.	Type of Reporting Person (See Instructions) IN

- (5) Includes (a) 108,789 shares owned directly by Mr. Robert Koski; (b) 53,086 shares owned by trusts which Mr. Koski serves as sole trustee as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (10,760 shares); The Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (10,760 shares); The Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (10,000 shares); and The Robert Clayton Koski Trust for the benefit of Robert Edward Koski (10,760 shares) and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (10,806 shares); and (c) 27,333 option shares able to be acquired upon the exercise of currently exercisable stock options granted pursuant to our Director compensation program.
- (6) Represents shares beneficially owned by the KFLP, of which Mr. Robert Koski is a general partner and may be deemed to have beneficial ownership. Mr. Koski disclaims beneficial ownership of the shares held by the KFLP except to the extent of his pecuniary interest for purposes of calculating the percent of the shares held by Mr. Koski includes the 27,000 shares Mr. Koski has the right to acquire based on currently outstanding and exercisable stock options.

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Beverly L. Koski
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3.	SEC Use Only
4.	Source of Funds (See Instructions) Not applicable
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6.	Citizenship or Place of Organization United States
Number of shares beneficially owned by each reporting person with	7. Sole Voting Power 2,800 (7) (See Item 5)
	8. Shared Voting Power 1,828,419 (1) (8) (See Item 5)
	9. Sole Dispositive Power 2,800 (7) (See Item 5)
	10. Shared Dispositive Power 1,828,419 (1) (8) (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 1,831,219 (See Item 5)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="checkbox"/>
13.	Percent of Class Represented by Amount in Row (11) 15.2% (2)
14.	Type of Reporting Person (See Instructions) IN

- (7) Represents 2,800 shares of Oragenics Inc. common stock held directly by Koski Management Inc. which Ms. Beverley Koski wholly owns.
- (8) Represents shares beneficially owned by the KFLP, of which Koski Management Inc. is a general partner. Ms. Beverly Koski is the sole shareholder of Koski Management, Inc. and disclaims beneficial ownership of the shares held by the KFLP except to the extent of her pecuniary interest through Koski Management, Inc.

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Thomas L. Koski
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3.	SEC Use Only
4.	Source of Funds (See Instructions) Not applicable
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6.	Citizenship or Place of Organization United States
Number of shares beneficially owned by each reporting person with	7. Sole Voting Power 91,967 ⁽⁹⁾ (See Item 5)
	8. Shared Voting Power 1,828,419 ⁽¹⁾ ⁽¹⁰⁾ (See Item 5)
	9. Sole Dispositive Power 91,967 ⁽⁹⁾ (See Item 5)
	10. Shared Dispositive Power 1,828,419 ⁽¹⁾ ⁽¹⁰⁾ (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 1,920,386 (See Item 5)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="checkbox"/>
13.	Percent of Class Represented by Amount in Row (11) 15.9% ⁽²⁾
14.	Type of Reporting Person (See Instructions) IN

⁽⁹⁾ Represents 91,967 shares of Oragenics Inc. common stock held directly by the reporting person.

⁽¹⁰⁾ Represents shares beneficially owned directly by the KFLP, of which Mr. Thomas Koski is a general partner and may be deemed to have beneficial ownership. Mr. Thomas Koski disclaims beneficial ownership of the shares held by the KFLP except to the extent of his pecuniary interest.

Item 1. Security and Issuer

This Amendment No. 11 to Schedule 13D (“Amendment No. 11”) amends and supplements the statement on Schedule 13D originally filed on July 8, 2009, (the “Original Schedule 13D”), as it was previously amended and supplemented by Amendment No. 1 filed on February 12, 2010, (“Amendment No. 1”), and Amendment No. 2 filed on August 6, 2010 (“Amendment No. 2”) and No. 3 filed on February 11, 2011 (“Amendment No. 3”), Amendment No. 4 filed on April 5, 2012 (“Amendment No. 4”), Amendment No. 5 filed on June 15, 2012 (“Amendment No. 5”), Amendment No. 6 filed on August 10, 2012 (“Amendment No. 6”), Amendment No. 7 filed on February 6, 2013 (“Amendment No. 7”), Amendment No. 8 filed on January 23, 2015 (“Amendment No. 8”), Amendment No. 9 filed on July 11, 2016 (“Amendment No. 9”), and Amendment No. 10 filed on February 14, 2018 (“Amendment No. 10”) together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment No. 8, Amendment No. 9 and Amendment No. 10 hereinafter, collectively, referred to as the “Schedule 13D”) by the Reporting Persons (as defined below) relating to the common stock, par value \$0.001 per share (“Common Stock”), of Oragenics, Inc., a Florida corporation (the “Issuer” or the “Company”). The principal executive offices of the Issuer are located at 4902 Eisenhower Boulevard, Suite 125, Tampa, Florida.

Item 2. Identity and Background

Item 2 of the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment No. 8, Amendment No. 9 and Amendment No. 10 are hereby amended and restated as follows:

This statement is being jointly filed by each of the following persons pursuant to Rule 13d-1(k) promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”):

- (1) Koski Family Limited Partnership (“KFLP”), a Texas partnership.
- (2) Christine L. Koski, the managing general partner of KFLP.
- (3) Robert C. Koski, a general partner of KFLP and a Director of the Issuer.
- (4) Beverly L. Koski, as sole shareholder of Koski Management Inc., a general partner of KFLP.
- (5) Thomas L. Koski, a general partner of KFLP.

KFLP is a Texas -based private family partnership principally engaged in the business of investing and managing its own private equity investments.

The business address for KFLP is 3525 Turtle Creek Boulevard, Unit 19-B, Dallas, Texas 75219.

Each of the individuals set forth in clauses (2) through (5) are United States citizens. The business address for each is c/o Koski Family Limited Partnership, 3525 Turtle Creek Boulevard, Unit 19-B, Dallas, Texas 75219.

KFLP and the individuals listed in clauses (2) through (5) above (collectively, the “Reporting Persons”) may constitute a “group” for purposes of Rule 13d-5 under the Exchange Act with respect to their beneficial ownership of the Common Stock and are collectively referred to as the “Reporting Group.” The Reporting Group expressly disclaims that they have agreed to act as a group other than as described in this statement. The Reporting Persons have entered into a Joint Filing Agreement, a copy of which was filed with the Original Schedule 13D and incorporated herein by reference. Information with respect to each Reporting Person is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person. This report on Schedule 13D constitutes an amendment to the original report of the Reporting Group.

During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration

The Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment No. 8, Amendment No. 9 and Amendment No. 10 are supplemented and amended by the information below.

This Amendment is being filed to report (i) the issuance of 4,000 restricted shares of common stock and 14,000 options to purchase common stock to Mr. Robert Koski by the Company under the Company's 2012 Equity Incentive Plan, to Mr. Koski as a non-employee director as part of the Company's director compensation program, the options do not vest until June 22, 2019 and; (ii) the change in beneficial ownership resulting from the Company's recently announced and completed public offering.

This Amendment is being filed to reflect the impact on the applicable Reporting Persons beneficial ownership of the Company's shares resulting from the above, which individually and in the aggregate are not considered to have resulted in a material change in the Reporting Persons beneficial ownership of Company shares.

Item 4. Purpose of Transaction

Item 4 of the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment 8 and Amendment 9 are supplemented and amended by the information below.

The information in Item 3 of this Amendment No. 9 is incorporated herein by reference.

All of the securities of the Issuer were acquired for investment purposes. The Reporting Persons intend to review on a continuing basis the investment in the Issuer. Based on such review, the Reporting Persons may acquire, or cause to be disposed, such securities at any time or formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, the Issuer's business, financial condition and operating results, general market and industry conditions or other factors.

Except as otherwise described in this Schedule 13D, none of the Reporting Persons currently has any plans or proposals that relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board except as may be required for the Company to comply with exchange listing requirements with respect to the number of independent directors; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) any changes in the Issuer's charter or by-laws or other actions which may impede the acquisition or control of the Issuer by any person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) any action similar to those enumerated above.

Item 5. Interest in Securities of the Issuer

Item 5 of the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment 8, Amendment 9 and Amendment No. 10 are supplemented and amended by the information below.

This Amendment No. 11 is being filed to reflect the impact on the applicable Reporting Persons beneficial ownership of the Company's share issuances resulting from (i) the issuance of 4,000 restricted shares of common stock and 14,000 options to purchase common stock to Mr. Robert Koski by the Company under the Company's 2012 Equity Incentive Plan, to Mr. Koski as a non-employee director as part of the Company's director compensation program and; (ii) the change in beneficial ownership resulting from the Company's recent public offering.

As of August 1, the Reporting Persons beneficially own an aggregate of 2,269,648 shares of Common Stock, or approximately 18.8% of the Common Stock then outstanding.

By virtue of their potential status as a "group" for purposes of Rule 13d-5, each of the members of the Reporting Group may be deemed to have shared voting and dispositive power over the shares owned by other members. Neither the filing of this statement nor any of its contents shall be deemed to constitute an admission that any Reporting Person is the beneficial owner of any Common Stock referred to in this statement for the purposes of Section 13(d) of the Act or for any other purpose, and such beneficial ownership is expressly disclaimed.

(a) and (b)

(1) The KFLP beneficially owns 1,828,419 shares of Common Stock (consisting of 1,286,483 shares owned directly and 541,936 shares able to be acquired upon conversion of Series B Preferred Stock and the exercise of warrants), constituting 15.1% of the Common Stock of the Issuer outstanding as of August 1, 2018. The KFLP may be deemed to have shared voting power and investment power with respect to all shares of Common Stock referred to above.

(2) Christine L. Koski as a general partner of the KFLP, may be deemed to be the beneficial owner of the shares of Common Stock beneficially owned by the KFLP, constituting approximately 15.1% of the Common Stock of the Issuer outstanding as of August 1, 2018. Ms. Koski may be deemed to have shared voting power and investment power with respect to such shares of Common Stock. Ms. Koski directly owns 157,254 shares of common stock. Ms. Koski has sole voting and investment power with respect to these shares. Ms. Koski's individual beneficial holdings constitute 1.4% of the Common Stock of the Issuer outstanding as of August 1, 2018 and together with the KFLP shares and warrants constitute 16.4%.

(3) Robert C. Koski as a general partner of the KFLP, may be deemed to be the beneficial owner of the 1,828,419 shares of Common Stock beneficially owned by the KFLP, constituting approximately 15.1% of the Common Stock of the Issuer outstanding as of August 1, 2018. Mr. Koski may be deemed to have shared voting power and investment power with respect to such shares of Common Stock. Mr. Koski directly beneficially owns 136,122 shares of common stock, consisting of 108,789 shares directly owned and 27,333 shares able to be acquired upon the exercise of stock options granted pursuant to our Director compensation program, of the Issuer outstanding as of August 1, 2018, Mr. Koski has 14,000 shares to be acquired upon the exercise of stock options which are not exercisable until June 22, 2019. Mr. Koski also may be deemed to be the beneficial owner of an aggregate of 53,086 shares of Common Stock owned by trusts of which Mr. Koski serves as sole trustee as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (10,760 shares); The Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (10,760 shares); The Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (10,000 shares); and The Robert Clayton Koski Trust for the benefit of Robert Edward Koski (10,760 shares) and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (10,806 shares). Mr. Koski has sole voting and investment power with respect to these shares. Mr. Koski's beneficial individual holdings together with the trust holdings constitute 1.6% of the Common Stock of the Issuer outstanding as of August 1, 2018 and together with the KFLP shares and warrants constitute 16.7%.

(4) Beverly L. Koski as the sole shareholder of Koski Management, Inc. (a general partner of the KFLP), may be deemed to be the beneficial owner of the 1,828,419 shares of Common Stock beneficially owned by the KFLP, constituting approximately 15.1% of the Common Stock of the Issuer outstanding as of August 1, 2018. Ms. Koski may be deemed to have shared voting power and investment power with respect to such shares of Common Stock referred to above. Koski Management, Inc. (solely owned by Beverly Koski) directly owns 2,800 shares of common stock. Ms. Koski has sole control of Koski Management, Inc. and thus sole voting and investment power with respect to these shares. Ms. Koski's individual beneficial holdings constitute less than one percent of the Common Stock of the Issuer outstanding as of August 1, 2018 and together with the KFLP shares and warrants constitute 15.2%.

(5) Thomas L. Koski as the general partner of the KFLP, may be deemed to be beneficial owner of the 1,828,419 shares of Common Stock beneficially owned by the KFLP, constituting approximately 15.1% of the Common Stock of the Issuer outstanding as of August 1, 2018. Mr. Koski may be deemed to have shared voting power and investment power with respect to such shares of Common Stock. Mr. Koski owns 91,967 shares of common stock. Mr. Koski has sole voting and investment power with respect to these shares. Mr. Koski's individual holdings constitute less than one percent of the Common Stock of the Issuer outstanding as of August 1, 2018 and together with the KFLP shares constitute 15.9%.

(c) To the best knowledge of the Reporting Persons, except for the transactions described in this statement, none of the Reporting Persons has effected any transactions in the securities of the Issuer during the past 60 days.

(d) Except as stated within this Item 5, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock reported by this statement.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The information set forth under Item 4 is hereby incorporated by reference.

Except for the agreements described above or in response to Items 3 and 4 of this Schedule 13D, which are hereby incorporated herein by reference, to the best knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the persons enumerated in Item 2 of this Schedule 13D, and any other person, with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option agreements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.

Item 7. Material to Be Filed as Exhibits

- Exhibit 99.1** Power of Attorney of the KFLP dated July 1, 2009.
- Exhibit 99.2** Power of Attorney of Christine L. Koski dated July 1, 2009.
- Exhibit 99.3** Power of Attorney of Robert C. Koski dated July 2, 2009.
- Exhibit 99.4** Power of Attorney of Thomas L. Koski dated July 2, 2009.
- Exhibit 99.5** Power of Attorney of Beverly Koski dated July 2, 2009.
- Exhibit 99.6** Joint Filing Agreement, dated July 8, 2009, by and among the Reporting Persons.

* Filed as Exhibits to the Form 8-K filed on November 9, 2017.

** Filed as Exhibits to the Original Schedule 13D filed on July 8, 2009 and incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate.

Dated: August 13, 2018

KOSKI FAMILY LIMITED PARTNERSHIP

By: /s/ Christine L. Koski*

Christine L. Koski
General Managing Member

/s/ Christine L. Koski*

Christine L. Koski

/s/ Robert C. Koski*

Robert C. Koski

/s/ Thomas L. Koski*

Thomas L. Koski

/s/ Beverly Koski*

Beverly Koski

*By: /s/ Mark A. Catchur

Mark A. Catchur
As Attorney-in-Fact

* Mr. Mark A. Catchur is signing as Attorney-in-Fact pursuant to powers of attorney dated July 1, 2009 and July 2, 2009 granted by each Reporting Person, copies of which are filed as exhibits to the Original Schedule 13D filed on July 8, 2009 and incorporated herein by reference.

Index of Exhibits

Item 7.	Material to Be Filed as Exhibits
Exhibit 99.1**	Power of Attorney of the KFLP dated July 1, 2009.
Exhibit 99.2**	Power of Attorney of Christine L. Koski dated July 1, 2009.
Exhibit 99.3**	Power of Attorney of Robert C. Koski dated July 2, 2009.
Exhibit 99.4**	Power of Attorney of Thomas L. Koski dated July 2, 2009.
Exhibit 99.5**	Power of Attorney of Beverly Koski dated July 2, 2009.
Exhibit 99.6**	Joint Filing Agreement, dated July 8, 2009, by and among the Reporting Persons.

* Filed as Exhibits to the Form 8-K filed on November 9, 2017.

** Filed as Exhibits to the Original Schedule 13D filed on July 8, 2009 and incorporated herein by reference.